journal article·2025-07-23

T-Cell-Derived Extracellular Vesicles with an Antitransferrin Receptor Antibody for Multicancer Targeting

Hanchae Cho, Hyunji Ju, Sanghee Shin, Yongdeok Ahn, Eunju Park, Inseong Jung, Sung-Min Kang, Soojeong Noh, Jiwon Shin, Jun-Kook Park, Jongwon Jeong, Daeha Seo, Byoung-Joon Song, Kyungmoo Yea, Moon-Chang Baek

Nano Letters· Volume 25· Issue 29
Publisher page

Abstract

Recent research has explored the anticancer properties of immune-cell-derived small extracellular vesicles (sEVs), but many challenges, like the need for improved targeting, remain. To address these challenges, we engineered T-cell-derived sEVs with antitransferrin receptor 1 (TfR1) antibodies (T-EVs). This modification enhanced the delivery of sEV to six types of cancer cells, as confirmed by flow cytometry, immunocytochemistry, live cell imaging, and blocking experiments in vitro . The T-EVs also reduced PD-L1 and Rab27a levels, decreased sEV production from breast cancer cells, and increased susceptibility to CD8 + T-cell-mediated cytotoxicity. Systemically administered T-EVs efficiently targeted breast, lung, and skin tumors in mouse models. Notably, T-EVs significantly inhibited tumor growth without systemic toxicity. Additionally, T-EVs reduced PD-L1 and Rab27a levels in cancer cells while enhancing the CD8 + T-cell cytotoxicity and proliferation. Overall, this study highlights the anticancer effects of T-EVs against multiple cancer types, underscoring their potential in developing targeted cancer therapies.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Extracellular vesicles in disease · Nanoplatforms for cancer theranostics · RNA Interference and Gene Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Biomedical Science

Kyungpook National University School of Medicine

Department of Molecular Medicine

CMRI, Kyungpook National University School of Medicine

Department of New Biology

Daegu Gyeongbuk Institute of Science & Technology

Department of Physics and Chemistry

Section of Molecular Pharmacology and Toxicology, Laboratory of Membrane Biochemistry and Biophysics

National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health (NIH)

Funding

Daegu Gyeongbuk Institute of Science and Technology · Ministry of Science and ICT, South Korea · National Institute on Alcohol Abuse and Alcoholism

References (40)

Show source-provided references
1. 10.1002/jev2.1240410.1002/jev2.12404 ↗
2. 10.1002/advs.20210322210.1002/advs.202103222 ↗
3. 10.1016/j.nantod.2015.04.00410.1016/j.nantod.2015.04.004 ↗
4. 10.1016/j.ymthe.2023.02.01310.1016/j.ymthe.2023.02.013 ↗
5. 10.1016/j.ymthe.2023.01.02110.1016/j.ymthe.2023.01.021 ↗
6. 10.1080/10717544.2022.210440410.1080/10717544.2022.2104404 ↗
7. 10.1186/s13046-022-02492-110.1186/s13046-022-02492-1 ↗
8. 10.1016/j.biomaterials.2022.12176510.1016/j.biomaterials.2022.121765 ↗
9. 10.1002/jev2.1235010.1002/jev2.12350 ↗
10. 10.1002/jev2.1228710.1002/jev2.12287 ↗
11. 10.1016/j.nantod.2023.10177110.1016/j.nantod.2023.101771 ↗
12. 10.1002/advs.20230055210.1002/advs.202300552 ↗
13. 10.1002/advs.20230361710.1002/advs.202303617 ↗
14. 10.1038/s41551-024-01214-610.1038/s41551-024-01214-6 ↗
15. Shen Y. · Am. J. Cancer Res. · 2018 · 8 · 916
16. 10.1016/j.ymthe.2021.03.02210.1016/j.ymthe.2021.03.022 ↗
17. 10.1371/journal.pone.003966610.1371/journal.pone.0039666 ↗
18. 10.3389/fimmu.2021.60769210.3389/fimmu.2021.607692 ↗
19. 10.3390/cells807072710.3390/cells8070727 ↗
20. Laurence, B.; Bensussan, A.; Kadouche, J. Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells. U.S. Patent WO2007000671A3, 2010.
21. 10.1016/j.jconrel.2011.01.01010.1016/j.jconrel.2011.01.010 ↗
22. 10.1016/j.canlet.2015.04.02610.1016/j.canlet.2015.04.026 ↗
23. 10.1080/20013078.2017.135464510.1080/20013078.2017.1354645 ↗
24. 10.1038/s41586-018-0392-810.1038/s41586-018-0392-8 ↗
25. 10.1016/j.cell.2019.02.01610.1016/j.cell.2019.02.016 ↗
26. 10.1016/j.ymthe.2024.09.02610.1016/j.ymthe.2024.09.026 ↗
27. 10.1002/jev2.1248010.1002/jev2.12480 ↗
28. 10.1002/jev2.1231210.1002/jev2.12312 ↗
29. 10.1002/jev2.1208510.1002/jev2.12085 ↗
30. 10.1038/s41598-018-24531-810.1038/s41598-018-24531-8 ↗
31. 10.1016/j.nantod.2019.02.00510.1016/j.nantod.2019.02.005 ↗
32. 10.1158/1535-7163.MCT-16-040810.1158/1535-7163.MCT-16-0408 ↗
33. 10.1126/sciadv.abj820710.1126/sciadv.abj8207 ↗
34. 10.1038/nature2234110.1038/nature22341 ↗
35. 10.1126/scitranslmed.abb698110.1126/scitranslmed.abb6981 ↗
36. 10.1158/1535-7163.MCT-21-019310.1158/1535-7163.MCT-21-0193 ↗
37. 10.1002/prp2.75710.1002/prp2.757 ↗
38. 10.1186/s13045-021-01182-310.1186/s13045-021-01182-3 ↗
39. 10.1038/s12276-023-01132-810.1038/s12276-023-01132-8 ↗
40. 10.1002/advs.20180221910.1002/advs.201802219 ↗